Astellas Pharma Europe Ltd

Commercial

Kirsten Leyland - Chief Investigator - Astellas Pharma Europe Ltd. - UKKirsten Leyland - Corresponding Applicant - Astellas Pharma Europe Ltd. - UKAmit Kiran - Collaborator - Astellas Pharma Europe Ltd. - UKBas van der Poel - Collaborator - Astellas Pharma Europe Ltd. - UKMatthias Stoelzel - Collaborator - Astellas Pharma Europe Ltd. - UK

CPRD474

Overactive bladder (OAB) is a condition affecting approximately 12% of UK adults, where patients experience increased urgency and frequency of urination, with or without incontinence. The current recommended treatment for OAB is for physicians to prescribe an inexpensive antimuscarinic (AM) agent first, and if that fails to try different AM treatments. The clinical benefit of patients ‘cycling’ through multiple AMs has not been clearly shown, and the burden of this recommendation on the UK healthcare system, in terms of usage and costs, is unknown.

Overactive bladder (OAB) syndrome, characterized by the core symptom of urinary urgency, affects more than 500 million people worldwide, with approximately 12% of UK adults affected. Current National Institute for Health and Care Excellence (NICE) and local formulary guidelines recommend first-line treatment with the lowest-cost antimuscarinic (AM) agent and, if that fails, they encourage ‘cycling’ through multiple antimuscarinic (AM) treatments, despite limited evidence of clinical effectiveness and the unknown healthcare burden placed on UK OAB patients. This study will describe healthcare resource use (HCRU), economic burden, demographic characteristics and treatment patterns in patients who cycle through AM treatments.

25/03/2021

Release